Northwire Canada EditionMonday, August 24, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% EML 0.225 −4.3% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% EML 0.225 −4.3%
Financings Routine −

MustGrow Increases Non-Brokered LIFE Offering to Approximately $3.7 Million

MustGrow Biologics raises $3.7M to fund TerraSante ramp-up amid persistent cash burn.

By The Northwire Desk — AI Analysis Jun 17, 2026 · 19:22 MGRO · 0.445 MustGrow Biologics Corp.
Executive Summary
  • MustGrow Biologics Corp. is proceeding with the closing of its previously announced non-brokered private placement (LIFE Offering) on June 18, 2026.
  • The company has increased the offering size from the previously announced $2 million to approximately $3.7 million.
  • Approximately 7.4 million units will be issued at $0.50 per unit.
  • Each unit consists of one common share and one common share purchase warrant exercisable at $0.70 per share for 60 months.
  • Net proceeds will fund inventory production for TerraSante, working capital, and general corporate purposes.
  • Finder compensation includes up to 6.0% cash and 6.0% in non-transferable warrants.
Material Impact
  • Dilution: The issuance of ~7.4 million units increases the fully diluted share count from ~76.7 million to ~84.1 million, representing approximately 9.6% dilution.
  • Pricing: The offering price of $0.50 is above the current market price of $0.44, which is atypical for a private placement and may indicate strong insider or committed investor participation, or a strategic pricing decision to minimize immediate discount dilution.
  • Liquidity: The $3.7 million in gross proceeds (net of finder fees) provides a critical lifeline, extending the company's runway by roughly one quarter given the Q1 2026 operating cash burn of $2.28 million.
  • Strategic: Confirms management's commitment to scaling TerraSante inventory and transitioning from batch to continuous manufacturing.
MGRO · Price
Company Overview
  • MustGrow Biologics Corp. is an agricultural biotechnology company focused on developing and commercializing mustard-derived biological products.
  • Core Product: TerraSante, an organic, OMRI-listed wettable powder biofertility product designed to improve soil microbiome health, nutrient use efficiency, and crop yields.
  • Pipeline: TerraMG, a biocontrol product targeting clubroot disease in canola, with promising field trial data showing up to 95% spore reduction and yield increases.
  • Strategic Shift: The company is winding down its Canadian distribution arm, NexusBioAg, to focus exclusively on scaling TerraSante sales in the U.S. market and pursuing international partnerships, including a collaboration with Bayer for EMEA.
Read the original news release →

More from MustGrow Biologics Corp.

Jun 19, 2026 · 17:01

MustGrow Biologics Raises $3.7M to Fund TerraSante Biofertility Ramp Amid Persistent Cash Burn

Financings May 28, 2026 · 17:01

MustGrow Biologics Secures Liquidity Amidst Early Revenue Growth and Manufacturing Transition

Earnings May 25, 2026 · 18:01

MustGrow Biologics Secures Capital for U.S. Expansion Amidst Revenue Growth

Financings May 25, 2026 · 07:00

Regulatory Expansion Validates Growth Strategy But Cash Burn Remains Critical Risk

Regulatory May 14, 2026 · 17:15

MustGrow Biologics Corp.

Other Apr 29, 2026 · 17:01

MustGrow Biologics Revenue Surges 19x Amidst Strategic Pivot and Cash Burn Concerns

Earnings